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Detection and reduction of inducible myocardial ischemia is a key moment in management
of patients with stable coronary artery disease. It has been shown that coronary angiography
as well as non-invasive stress testing fails to inform about true hemodynamic significance of
individual stenosis in certain subsets of coronary anatomies. Intervention of non-significant
lesion is associated with worse prognosis than optimal medical treatment. Using invasive
measurement of myocardial fractional flow reserve (FFRmyo) for decision to perform or
defer percutaneous coronary intervention was superior to angiographical guidance. Revas-
cularization of functionally significant lesions and medical management of non-significant
ones is the base of concept of functional revascularization and FFRmyo may be a tool, which
provides information needed for such clinical decision.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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It has been documented that the presence of significant myo-
cardial ischemia is a negative prognostic factor in patients with
stable coronary artery disease (CAD).[1–3] Reduction of ischemic
burden is associated with improved long-term prognosis. It can
be successfully achieved bymedical therapy or revascularizationch Society of Cardiology.
).procedures.[3] The nuclear sub-study of the COURAGE trial [4] as
well as other studies demonstrated better efficiency of percuta-
neous coronary intervention (PCI) or coronary artery bypass
grafting (CABG) when compared to medical treatment in
relieving myocardial ischemia. [3,5]. In certain subsets of
patients (left main disease, triple-vessel disease), CABG is
able to improve the patient’s prognosis when comparedPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
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though for clinical practice still relevant trials [5–7]. When
deciding on indication and possibly type of revascularization
invasive coronary angiography still plays a pivotal role.
It is well established, relatively safe and available method,
which offers very good temporal and spatial resolution
and has been used as a road map for revascularization
procedures for several decades. Thought for many years
it has been also recognized that the ability of coronary
angiography to define functional significance of coronary
stenosis is rather limited. Coronary lesions with 40–70%
stenosis diameter were found to be both significant and
non-significant. [8–10]. Despite of the recent development of
techniques of coronary angiography and image post-proces-
sing, including 2D a 3D quantitative analysis or computed
tomography coronary angiography, there is still a substantial
limitation of contrast angiography in assessment of func-
tional significance. [11,12] Further, many physicians still
rely only on visual estimation of coronary stenosis even
though it has been shown to be unreliable [11,12]. Many
patients undergoing coronary angiography have not
been non-invasively tested for inducible myocardial ischemia
or these test were not conclusive [13]. In some patients
with multi vessel disease it may not be possible to make a
sound relation between stress test result and coronary
anatomy or result could be false negative due to balanced
ischemia.2. Myocardial fractional flow reserve
The myocardial fractional flow reserve (FFRmyo) is an inva-
sive method for an assessment of functional significance ofTable 1 – Clinical outcomes in the DEFER(26) and the COURAGE
non-ischemic FFR treated by PCI. At the time when trial was d
measurement is safe. Of interest are the differences between
conservative arm of COURAGE (probably mix of ischemic and
DEFER 5 years (n¼
Conservative
FFRZ0.75
Mortality (all cause) (%) 6.6
Mortality (cardiac)% 3.3
Spontaneous myocardial infarction (%) 0
Revascularization (%) 8.9
MortalityþSpontaneous myocardial infarction (%) 6.6
FFR–myocardial fractional flow reserve,OMT–optimal medical treatment
Table 2 – Outcome of patients in FAME study- 2 years follow-
stenting groups.
Ang
Mortality (all-cause) (%) 19
Myocardial infarction (%) 48
CABG, repeated PCI (%) 61
MortalityþMyocardial infarction (%) 63
MortalityþMyocardial infarction,CABG, repeated PCI (%) 110epicardial coronary artery stenosis and has been used in
clinical practice for more than a decade. It is based on
intracoronary pressure measurement during pharmacologi-
cally induced maximal hyperemia using dedicated coronary
micromanometric guidewire. [14–18] The position of micro-
manometr can be easily assessed during angiography, thus
allowing very good spatial resolution and assessment of
individual lesions and diseased arteries. FFRmyo could be
considered as ‘‘in-cathlab’’ surrogate for stress testing as it
was found to have an excellent sensitivy and specificity when
compared to conventional stress test such as myocardial
perfusion scans, stress echocardiography and ECG stress
testing. [16,19].
Probably main clinical application of FFRmyo is an assess-
ment of borderline significant stenosis and this indication is also
supported by recently published guidelines. [20,21] Several
published data suggested that deferral of intervention of border-
line stenosis with FFR value more than 0.75 or 0.80 is safe and
associated with very good outcome during mid- and long-term
follow-up. [12,22–25]. The very first randomized trial using
FFRmyo in relatively low-risk patients (the DEFER trial) docu-
mented better outcome in patients with deferred PCI when
compared to stented group with ischemic FFRmyo and control
stented group with non-ischemic FFRmyo [26]. (Table 1).
Landmark trial FAME published in 2009, included 1005
patients with multi-vessel disease and randomized them to
angiography- or FFR-guided PCI patients randomized to
undergo FFR had absolute reductions in the primary compo-
site end point of death, MI, CABG surgery, or repeat PCI of
5.1% and 5.3% at one year and 18 months, respectively
(Table 2).
At two years, the 22.2% of patients randomized to angio-
graphy-guided PCI had a primary end point compared with(29) trials. In DEFER trial there was a group of patient with
esigned it was not clear that deferral of PCI based on FFR
conservative arm of DEFER (non-ischemic lesions) and
non-ischemic lesions).
325) COURAGE 4.6 years (n¼2287)
PCI FFRZ0.75 PCI FFRr0.75 PCI Conservative
(OMT)
5.7 9.0 7.6 8.3
2.3 6.0 2.1 2.2
5.6 9.7 10.0 11.4
9.1 13.4 21.1 32.6
11.3 18.7 17.6 19.7
. PCI–percutaneous coronary intervention.
up(27) comparing results in angio-guided and FFR-guided
io-guided (n¼496) FFR-guided (n¼509) P
(3.8) 13 (2.6) 0.25
(9.7) 31 (6.1) 0.03
(12.3) 53 (10.4) 0.35
(12.7) 54 (10.4) 0.03
(22.2) 90 (17.7) 0.07
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 1 6 2 – e 1 6 6e16417.7% in the FRR-guided treatment arm, an absolute reduc-
tion of 4.5%. Similar to earlier analyses, the reduction was
driven by a reduction in the rate of MI. The cost-analysis
showed that the treatment with FFR was cost-effective,
mainly because patients in the FFR arm received fewer stents.
The rate of complication related to lesion with deferred PCI
was low with only 1 MI related to deferred stenosis (out of 517
deferred lesions). The cut-off value of FFRmyo for PCI was
0.80 and less. [10,27].
There were 3 large randomized trials comparing different
revascularization strategies (multi-vessel PCI versus CABG in
SYNTAX trial [28]) or comparing revascularization with opti-
mal medical treatment (OMT) (COURAGE trial [29]) and
above mentioned FAME trial [27]. After excluding patients
with left main disease from the SYNTAX trial and including
only patients with triple-vessel disease (SYNTAX 3VD) a
comparison of these trials regarding the incidence of major
adverse cardiac events (MACE) could be made. Despite of
different angiographical baselines (more advanced anatomy
in SYNTAX 3VD) the rate of MACE in PCI arms of all these
trials was similar at around 20% at 1-year follow-up. FFR
guided strategy in FAME trial had 13% of MACE. Hypotheti-
cally one of the factors causing this difference could be a
non-necessary stenting in SYNTAX 3VD, COURAGE and FAME
angio-guided arm populations, where stented lesions were
not functionally significant despite of their angiographic
appearance.3. Concept of functional revascularization
To understand the concept of functional revascularization in
patients with stable CAD is important to acknowledge differ-
ent combined mortality and MI rate associated with ischemicFig. 1 – Angiogram of the left coronary artery. There are proxima
LAD–0.64 indicating hemodynamic significance.and non- ischemic stenoses and their treatment (medical
versus interventional). From previous studies is known that
such an event rate is &1% per year for a functionally non-
significant stenosis if treated appropriately by medication.
[26,29–31]. Conversely it is between 5% and 10% per year for a
functionally significant stenosis if only treated by medica-
tion[4,32] and approximately 3% per year for a stented lesion
whether it was functionally significant or not [4,30,32,33].
This means that stenting of a functionally significant
stenosis could improve outcome, but stenting a functionally
non-significant stenosis would worsen outcome.
It may also change a routine practice in coronary cardiac
surgery [31]. Cornelis et al. showed that 1-year patency of
venous grafts depends also on lesion functional significance
when assessed by FFRmyo. The occlusion rate was strikingly
higher in non-significant lesions[34]. By avoiding unneces-
sary grafting some patients could be treated by PCI instead or
having less grafts, possibly all arterial. Recently presented
large French FFR registry documented such a trend in clinical
practice [35].4. Case report
This gentleman, who is 74 years old, was referred for cardiac
catheterization. His main complain were palpitations sec-
ondary to persistent atrial fibrillation, which were occasion-
ally associated with chest dyscomfort. He denied exertional
chestpains. He had refused to undergo ablation therapy for atrial
fibrillation in the past. His coronary angiography revealed two-
vessel disease. There was a 50–70% of proximal left anterior
descending (LAD) and serial 50% stenosis of left circumflex artery
(LCx). Right coronary artery had mild disease.l stenoses of LAD (arrows). Bottom left–FFRmyo recording in
Fig. 2 – Angiogram of the left coronary artery. There are proximal stenoses of LCx and obtuse marginal branch (arrows).
Bottom left–FFRmyo recording in LCx. The value of 0.84 does not suggest hemodynamic significance.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 1 6 2 – e 1 6 6 e165FFRmyo of both arteries was performed using intracoronary
bolus of Adenosine, 150 mg. FFR of LAD was 0.64 (Fig. 1),
FFRmyo of LCx was 0.84 (Fig. 2). The patient was referred for
single coronary bypass (LIMA-LAD) and MAZE procedure.
Disease of LCx should be managed medically.5. Conclusion
There could be a shift of paradigm for indication of revascu-
larization in patients with stable CAD. Functional measure-
ment prior to indication of revascularization may decrease
the rate of implanted stents or inserted grafts. It could also
change the classification of patient according to number of
diseased vessels, usually down-grading as less stenoses were
functionally significant. It is not realistic to advocate FFR
measurement for all stenoses in range 40–70% and also
expect that measurement of all borderline stenosis would
have significant impact on daily routine practice. Yet it is
important to recognize that initial data suggest that FFRmyo
could be a valuable tool in these clinical situations with
potential to improve patient outcome.
In the future we will get more data from FAME2 trial
comparing PCI and OMT and we need more adequately
designed trials comparing PCI and CABG in different patient
subsets.
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